DEFA14A ·Filed Mar 27, 2026

RARE

Ultragenyx Pharmaceutical Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed6mo ago SEC0001308179-26-000175
Proxy solicitation materials
Actionable Insight • Neutral

This is a routine administrative filing. Traders should note the upcoming annual meeting but do not need to take any immediate action based on this filing. Monitor for the actual proxy statement and annual report for any material updates.

DirectionNeutral
Confidencelow
Horizonimmediate
Final — all horizons settled through T+60d
RARE ▲ +51.55% at T+60d
NEUTRAL call ✓ call won +51.55% · α vs SPY +35.06% · entry $19.30 → $29.25
Entry anchored
Mar 27, 03:59 PM ET
via exchange tick
T+1d
+8.55%
call +8.55% · α +5.66%
$20.95
settled 6mo ago
T+5d
+19.95%
call +19.95% · α +15.65%
$23.15
settled 6mo ago
T+20d
+27.10%
call +27.10% · α +14.50%
$24.53
settled 5mo ago
T+60d
+51.55%
call +51.55% · α +35.06%
$29.25
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Ultragenyx Pharmaceutical Inc. (RARE) has filed a definitive additional proxy soliciting material (DEFA14A) for its 2026 Annual Meeting. The filing is routine and contains standard voting instructions for shareholders, including a notice to vote on proposals by May 13, 2026, and information on how to access meeting materials. There is no material financial data or significant corporate action disclosed.

Key Facts

  • Filing is a DEFA14A, which is a definitive additional proxy soliciting material.
  • It is for the 2026 Annual Meeting of shareholders.
  • The document contains a notice to vote by May 13, 2026, and instructions on how to access the proxy statement and annual report.
  • The filing is routine and does not contain any new financial information or significant corporate announcements.

Financial Impact

No material financial impact disclosed.

Risk Factors

  • None disclosed in this filing.
  • The filing is routine and does not indicate any immediate risks.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001308179-26-000175
Document: 0001308179-26-000175-index.html0001308179-26-000175
Document: 0001308179-26-000175.txt0001308179-26-000175
12 reports for RARE
Performance horizon
83% Hit rate 5 of 6 directional calls best @ T+60▲ +48.73%Apr 2, 2026
Filters
Rows
Reports for RARE — sortable, filterable
TypeNow
Sep 2, 2026
4w ago
8-K
BEARISH ★ 8/10
$14.85 $15.22▼ −2.49%▼ −3.68%$15.22 (−2.49%)
Sep 1, 2026
4w ago
Press Release
BULLISH ★ 7/10
$26.53 $15.03▼ −43.35%▼ −43.02%$15.22 (−42.63%)
Aug 11, 2026
7w ago
8-K
NEUTRAL ★ 4/10
$26.80 $14.31▼ −46.60%▼ −45.55%$15.22 (−43.21%)
Aug 4, 2026
8w ago
8-K
BULLISH ★ 6/10
$24.93 $26.53▲ +6.42%▲ +7.02%$15.22 (−38.95%)
Aug 4, 2026
8w ago
Insider Cluster
NEUTRAL ★ 2/10
$25.81 $25.81· 0.00%▲ +1.24%$15.22 (−41.03%)
Jun 15, 2026
15w ago
Insider Cluster
NEUTRAL ★ 2/10
$24.85 $32.03▲ +28.89%▲ +28.69%$15.22 (−38.75%)
Jun 11, 2026
16w ago
Institutional Cluster
NEUTRAL ★ 4/10
$23.98 $34.61▲ +44.33%▲ +42.44%$15.22 (−36.53%)
May 5, 2026
21w ago
Press Release
BEARISH ★ 6/10
$25.93 $22.41▲ +13.57%▲ +16.36%$15.22 (+41.30%)
May 1, 2026
22w ago
Insider Cluster
NEUTRAL ★ 2/10
$24.77 $22.85▼ −7.75%▼ −13.04%$15.22 (−38.55%)
Apr 2, 2026
26w ago
8-K
BULLISH ★ 8/10
$22.45 $24.69▲ +9.98%▲ +0.10%$15.22 (−32.20%)
Showing 10 of 12

US Market Status

Market Closed — Opens Mon (64h 20m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access